Sotalol IV is an intravenous antiarrhythmic agent indicated for substitution of oral treatment in patients who are unable to take the orally administered treatment.
Intravenous treatment is indicated for maintenance of normal sinus rhythm in patients with history of highly symptomatic atrial fibrillation/flutter and treatment of documented life-threatening ventricular arrhythmia.
An arrhythmia is an abnormal heart rhythm which results from disorders of heart impulse generation, from disorders of heart impulse conduction or from the combination of both.
Ventricular tachycardia (VT) or ventricular fibrillation (VF) refers to any rhythm faster than 100 (or 120) beats/min, with 3 or more irregular beats in a row, arising distal to the bundle of His. The rhythm may arise from working ventricular myocardium, the distal conduction system, or both. The trigger for ventricular tachycardia may be a premature ventricular beat due to an impulse generation disorder.
Atrial fibrillation (AF) is a common type of heart rhythm abnormality. In this condition, the heart rhythm is fast and irregular. AF is a quivering or irregular heartbeat (arrhythmia) that can lead to blood clots, stroke, heart failure and other heart-related complications.
To know more about Sotalol IV or place an order, visit altathera.com